Compare SKYW & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYW | ITRM |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 24.3M |
| IPO Year | 1994 | 2018 |
| Metric | SKYW | ITRM |
|---|---|---|
| Price | $89.32 | $0.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $122.00 | $9.00 |
| AVG Volume (30 Days) | 293.1K | ★ 882.9K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.20 | ★ 57.43 |
| EPS | ★ 10.35 | N/A |
| Revenue | ★ $2,971,963,000.00 | N/A |
| Revenue This Year | $8.47 | N/A |
| Revenue Next Year | $3.57 | $947.65 |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $74.70 | $0.14 |
| 52 Week High | $123.94 | $1.42 |
| Indicator | SKYW | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 38.75 | 20.39 |
| Support Level | $87.16 | N/A |
| Resistance Level | $103.50 | $0.39 |
| Average True Range (ATR) | 2.77 | 0.02 |
| MACD | 0.32 | -0.00 |
| Stochastic Oscillator | 26.54 | 6.76 |
SkyWest Inc offers commercial air services in the United States, Canada, Mexico, and the Caribbean. Additionally, it leases aircraft to capable users to help generate revenue. SkyWest generally provides regional flights and utilizes smaller, lower-cost aircraft to carry passengers who book tickets through partner airlines. It partners with carriers to fly and operate aircraft for a fee and may use the carriers' brands and ground support to coordinate marketing and transport passengers. The company has two reportable segments: SkyWest Airlines and SWC, which generate maximum revenue, and SkyWest Leasing activities.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.